A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis
Placebo for Emtricitabine/Tenofovir DisoproxilPlacebo for MK-8527TENOFOVIR DISOPROXIL AND EMTRICITABINEMK-8527 F1
Eligibility
Age group
18-64 years, 65+ years, 0-17 years
Sex
Female, Male
Primary endpoint
Number of Participants With Adjudicated Human Immunodeficiency Virus Type 1(HIV-1) Infection, Number of Participants Who Experience At Least One Adverse Event (AE), Number of Participants Who Discontinue Study Intervention Due to an AE
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.